U.S. regulators will ask outside experts if the agency should revoke approval of Abbott Laboratories’ heart medicine Trilipix for use with a cholesterol-lowering statin drug, according to draft questions released on Monday. Other actions for the advisory panel to consider are allowing continued marketing of Trilipix with a statin while adding results of a study known as Accord-Lipid to the drug label, or making no label changes.
